Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
The Japanese Cabinet on March 6 agreed to schedule the first rollout of the amended Pharmaceuticals and Medical Devices (PMD) Law for September 1, followed by the second and third step of enforcement on August 2021 and December 2022. The…
To read the full story
Related Article
- MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
- Amended PMD Law Promulgated, 3-Step Enforcement to Begin Next Year
December 5, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
- Health Minister Keen on Passage of PMD Law Amendment in Extra Diet Session
October 8, 2019
- As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
October 7, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
REGULATORY
- Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
May 15, 2026
- MHLW’s Mori Vows to Make Japan Pharma Market “More Attractive”
May 15, 2026
- MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
- Oncolys’ Telomelysin Up for Japan Panel Review on May 21
May 15, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…